IMMUTEP PRESENTS POSITIVE INTERIM DATA FROM PHASE II TACTI-002 TRIAL AT SITC
-
Part A comprises NSCLC patients with all levels of PD-L1 expression, being an all comer trial
-
Preliminary Overall Response Rate (ORR) of 41% from stage 11 of Part A
-
ORR compares favourably to standard of care treatments for all comer PD-L1 NSCLC patients
-
Twelve patients (71%) continuing treatment in stage 1 of Part A with a median follow-up of 5.6 months and no patient with a partial response progressing thus far
-
Recruitment started for stage 2 of Part A and is ongoing for stage 1 in Parts B and C
-
More mature data from TACTI-002 to be reported in Q1 of 2020
For further information please download the attached PDF:
Download this document
